You are here: Home » Current Affairs » Coronavirus » News
Business Standard

DCGI allows Serum to enrol 7-11 year olds in Covid vaccine trial

So far, only drugmaker Zydus Cadila's DNA Covid vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above

Topics
Coronavirus | Coronavirus Vaccine | Serum Institute of India

Reuters  |  Bengaluru 

Along with shorter-lasting antibodies, Covid vaccines also trigger what’s essentially a long-term memory in the immune system. (Photo: Bloomberg)
Representative image of Covid vaccine shots (Agencies/File)

India's drug regulator on Tuesday allowed vaccine maker Serum Institute to enrol kids aged 7-11 years for its COVID-19 vaccine trial as the country prepares to protect children from the

It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion.

"After detailed deliberation, the committee recommended for allowing enrolment of subjects of 7 to 11 years of age group as per the protocol," a subject expert panel of the Central Drugs Standard Control Organization said.

Serum Institute is already conducting a trial of its COVID-19 vaccine, a domestically produced version of AstraZeneca's shot, in the 12-17 age group and has presented safety data for an initial 100 participants.

So far, only drugmaker Zydus Cadila's DNA COVID-19 vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, September 28 2021. 13:44 IST
RECOMMENDED FOR YOU